

Assay	What it Detects	What it Doesn't Detect	TAT <sup>i</sup>	When to Use
<b>G-Banded Karyotyping</b>	<ul style="list-style-type: none"> <li>Microscopic genomic abnormalities (&gt;5-10 Mb)               <ul style="list-style-type: none"> <li>Inversions</li> <li>Duplications/deletions</li> <li>Balanced and unbalanced translocations</li> <li>Aneuploidies</li> </ul> </li> <li>&gt;10% mosaicism (for example: cultures where &gt;1 of 10 cells are <u>trisomy 12</u>)</li> </ul>	<ul style="list-style-type: none"> <li>Submicroscopic genomic abnormalities (&lt;5 Mb)</li> </ul>	7-10 days	<ul style="list-style-type: none"> <li>As a baseline genomic screen               <ul style="list-style-type: none"> <li>At derivation of cell lines</li> <li>At the start of experimental protocols</li> <li>To assess and monitor genomic stability (for example: every 5-10 passages of cell culture)</li> <li>At conclusion of experiments (prior to publication)</li> <li>For cell line banking</li> </ul> </li> <li>When publication-quality karyotypes are needed</li> </ul>
<b>Spectral Karyotyping (SKY)</b>	<ul style="list-style-type: none"> <li>Microscopic genomic abnormalities (&gt;5-10 Mb)               <ul style="list-style-type: none"> <li>Balanced and unbalanced translocations</li> <li>Aneuploidies</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Submicroscopic abnormalities (&lt;5 Mb)</li> <li>Inversions</li> <li>Duplications/deletions</li> </ul>	10-15 days	<ul style="list-style-type: none"> <li>As an adjunct to g-banded karyotyping               <ul style="list-style-type: none"> <li>To define complex rearrangements</li> <li>To identify marker chromosomes</li> </ul> </li> <li>When publication-quality spectral karyotypes are needed</li> </ul>
<b>CGH + SNP Microarray and CGH Microarray</b>	<ul style="list-style-type: none"> <li>Microscopic genomic abnormalities (&gt;5-10 Mb)</li> <li>Genomic gains and losses (&gt;50 Kb)               <ul style="list-style-type: none"> <li>Copy number variants</li> <li>Duplications/deletions</li> <li>Unbalanced translocations</li> <li>Aneuploidies</li> </ul> </li> <li>&gt;~10% mosaicism (for example: cultures where &gt;1 of 10 cells are trisomy 12)</li> <li>Loss of Heterozygosity (LOH) - detected by CGH + SNP</li> </ul>	<ul style="list-style-type: none"> <li>Balanced translocations</li> <li>Inversions</li> <li>&lt;~10% culture mosaicism (for example: cultures where 1 of 10 cells is trisomy 12)</li> <li>Chromosomal position of genomic gains</li> <li>Loss of Heterozygosity (LOH) - not detected by CGH alone</li> </ul>	14-21 days	<ul style="list-style-type: none"> <li>As a baseline genomic screen               <ul style="list-style-type: none"> <li>To detect submicroscopic (&lt;5 Mb) abnormalities</li> <li>To identify amplified or deleted genes of interest</li> </ul> </li> <li>In conjunction with g-banded karyotyping               <ul style="list-style-type: none"> <li>To define unbalanced translocation breakpoints</li> </ul> </li> <li>For research of genomic copy number change               <ul style="list-style-type: none"> <li>To identify structural variation within populations or disease cohorts</li> <li>To develop a cell line copy number variant profile</li> </ul> </li> </ul>
<b>Fluorescence In Situ Hybridization (FISH)</b>	<ul style="list-style-type: none"> <li>Genomic sequence of interest               <ul style="list-style-type: none"> <li>Duplications or deletions &gt;20 Kb</li> <li>&gt;2% mosaicism (for example: cultures where &gt;2 of 100 cells are trisomy 12)</li> <li>Chromosomal location of genomic gains</li> <li>Chromosome fusions (breakaparts)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Changes in regions other than the probe-specific sequence</li> </ul>	10-15 days	<ul style="list-style-type: none"> <li>To confirm findings and refine breakpoints detected by g-banded karyotyping</li> <li>To confirm findings and localize genomic gains detected by aCGH analysis</li> <li>As a screen for microdeletions/duplications of known targets</li> </ul>
<b>Fast FISH</b>	<ul style="list-style-type: none"> <li>Greater than 50% of recurrent trisomies in both human ES and iPS cell lines.<sup>ii</sup> <ul style="list-style-type: none"> <li>Trisomies of human chromosomes X, 8, 12 and 17.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Aneuploidies of chromosomes other than X, 8, 12 and 17</li> <li>Structural chromosome abnormalities</li> </ul>	1-2 days	<ul style="list-style-type: none"> <li>As a rapid screen for large numbers of clones</li> <li>As a cost-effective tool for monitoring aneuploidy</li> </ul>
<b>Short Tandem Repeat Analysis (STR)</b>	<ul style="list-style-type: none"> <li>STR polymorphisms for 15 loci plus amelogenin (Promega® PowerPlex® 16)</li> <li>Probability of matching identity to an existing STR profile</li> </ul>	<ul style="list-style-type: none"> <li>STR polymorphisms in areas other than those represented in Promega® PowerPlex® 16</li> </ul>	10-15 days	<ul style="list-style-type: none"> <li>To monitor identity of a cell line</li> <li>To confirm relationship of iPS cells to their parent line</li> <li>To establish an STR profile of a newly derived or reprogrammed cell line</li> <li>To rule out culture cross-contamination</li> </ul>

<sup>i</sup> Turn-around times provided are based on provision of sufficient mitotically active hES or iPS cultures grown in matrigel/TeSR or MEF/hES media conditions.

<sup>ii</sup> Based on n=1220 hES/iPS cell cultures karyotyped by WiCell Cytogenetics Laboratory.